NEW YORK, July 31, 2014 /PRNewswire/ - Canaccord Genuity is pleased to announce that Marko Kozul, M.D. has agreed to join its Equity Research team as a Managing Director covering biotechnology companies.
"The addition of Dr. Marko Kozul complements our existing global coverage of the Healthcare sector and affirms our commitment to providing clients with high quality, independent equity research coverage in dynamic growth sectors," stated Dan Daviau, President of Canaccord Genuity Inc. (US). "In addition to an established track record in equity research, Marko brings deep clinical and advisory experience to his role, which gives him an advanced understanding of the industry drivers impacting his coverage universe."
Based in the firm's San Francisco office, Dr. Kozul will focus on companies with advanced biotechnology platforms in the areas of neurology, immunology, obesity, oncology, and orphan infectious diseases. He joins senior Healthcare analysts John Newman and Corey Davis, building upon the firm's existing US life science practice.
Dr. Kozul joins Canaccord Genuity from Leerink Partners where he served as a senior biotechnology analyst and was previously analyst at ThinkEquity Partners and Jefferies & Company. Earlier in his career, he worked as the Research Director for Variant Medical Consulting Group and as a consultant for the Medical & Referral Source Inc. Dr. Kozul earned a Bachelor of Science in Cellular & Molecular Biology from the University of Michigan and an M.D. from the School of Medicine at International University of the Health Sciences. He is a member in good standing of the American Medical Association, the American Society of Clinical Oncology and the American Association for Cancer Research, the American Society of Hematology and the American Academy of Ophthalmology.
Canaccord Genuity's global equity research team now includes nine senior healthcare analysts across three continents, covering Biotechnology, Specialty Pharmaceuticals, Medical Devices, Medical Diagnostics, Life Sciences Tools and Healthcare Services. At present, Canaccord Genuity has nearly 150 equity research professionals globally and more than 950 companies under coverage.
ABOUT CANACCORD GENUITY:
Canaccord Genuity is the global capital markets division of Canaccord
Genuity Group Inc. (TSX: CF, LSE: CF.), offering institutional and
corporate clients idea-driven investment banking, merger and
acquisition, research, sales and trading services from offices in 10
countries worldwide. Our team of nearly 1,000 capital markets and
advisory professionals has industry and transactional expertise in 18
key sectors of the global economy. We are committed to providing valued
services to our clients throughout the entire lifecycle of their
business and operating as a gold standard independent investment bank -
expansive in resources and reach, but targeted in industry expertise,
market focus and individual client attention.
More information is available at www.canaccordgenuity.com.
ABOUT CANACCORD GENUITY GROUP INC.:
Through its principal subsidiaries, Canaccord Genuity Group Inc. (the
"Company") is a leading independent, full-service financial services
firm, with operations in two principal segments of the securities
industry: wealth management and capital markets. Since its
establishment in 1950, the Company has been driven by an unwavering
commitment to building lasting client relationships. We achieve this by
generating value for our individual, institutional and corporate
clients through comprehensive investment solutions, brokerage services
and investment banking services. The Company has offices in 10
countries worldwide, including Wealth Management offices located in
Canada, Australia, the UK and Europe. Canaccord Genuity, the
international capital markets division, operates in Canada, the US, the
UK, France, Germany, Ireland, Hong Kong, China, Singapore, Australiaand Barbados. To us there are no foreign markets.™
Canaccord Genuity Group Inc. is publicly traded under the symbol CF on the TSX and the symbol CF. on the London Stock Exchange.
SOURCE Canaccord Genuity Inc.
